Cargando…

A fully caninised anti-NGF monoclonal antibody for pain relief in dogs

BACKGROUND: Monoclonal antibodies are a major class of biological therapies in human medicine but have not yet been successfully applied to veterinary species. We have developed a novel approach, PETisation, to rapidly convert antibodies for use in veterinary species. As an example, anti-nerve growt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gearing, David P, Virtue, Elena R, Gearing, Robert P, Drew, Alexander C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834884/ https://www.ncbi.nlm.nih.gov/pubmed/24206926 http://dx.doi.org/10.1186/1746-6148-9-226

Ejemplares similares

In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti‐Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats
por: Gearing, D.P., et al.
Publicado: (2016)

A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain
por: Lascelles, B Duncan X, et al.
Publicado: (2015)

Tanezumab: Finally a Monoclonal Antibody for Pain Relief
por: Nair, Abhijit S
Publicado: (2018)

Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats
por: Enomoto, Masataka, et al.
Publicado: (2019)

A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study
por: Gruen, M.E., et al.
Publicado: (2016)

Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
por: Mason, Nicola J., et al.
Publicado: (2021)

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

A Fully Human Inhibitory Monoclonal Antibody to the Wnt Receptor RYK
por: Halford, Michael M., et al.
Publicado: (2013)

The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain
por: Xu, L., et al.
Publicado: (2016)

Histological Confirmation of Myelinated Neural Filaments Within the Tip of the Neurotrophic Electrode After a Decade of Neural Recordings
por: Gearing, Marla, et al.
Publicado: (2020)

Monash at the academic industrial interface: trains and platforms
por: Smith, Alexander Ian, et al.
Publicado: (2009)

Pain as relief
por: Vázquez, P. García, et al.
Publicado: (2021)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Natural anti-inflammatory agents for pain relief
por: Maroon, Joseph C., et al.
Publicado: (2010)

NGF – the TrkA to successful pain treatment
por: Kumar, Vinayak, et al.
Publicado: (2012)

Myelin goes to great pains to regulate NGF
por: Short, Ben
Publicado: (2015)

Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells
por: Saha, Nayanendu, et al.
Publicado: (2023)

Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B
por: Matsumura, Takuhiro, et al.
Publicado: (2020)

Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase
por: Kaewchim, Kanasap, et al.
Publicado: (2021)

A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers
por: Kostic, Ana, et al.
Publicado: (2017)

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10
por: Maskus, Dominika J, et al.
Publicado: (2015)

Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
por: Lou, Beilei, et al.
Publicado: (2021)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
por: Gibbs, John P., et al.
Publicado: (2016)

Palmitoyl-glucosamine co-micronized with curcumin for maintenance of meloxicam-induced pain relief in dogs with osteoarthritis pain
por: della Rocca, Giorgia, et al.
Publicado: (2023)

Pain relief can be painful
por: Bindra, Ashish, et al.
Publicado: (2015)

Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzhiemer’s disease model
por: Wu, Zheng, et al.
Publicado: (2014)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma
por: Kamoto, Satoshi, et al.
Publicado: (2020)

Estrogen Regulation of the Expression of Pain Factor NGF in Rat Chondrocytes
por: Shang, Xiushuai, et al.
Publicado: (2021)

The pain relief handbook /
por: Wells, Chris
Publicado: (1998)

Swallowing pain relief
por: LeBrasseur, Nicole
Publicado: (2002)

PAIN RELIEF IN CANCER
Publicado: (1984)

Sympathectomy for the Relief of Pain
por: Bingham, John A. W.
Publicado: (1948)

Pain Relief in Neonates
por: Krishnan, Lalitha
Publicado: (2013)

Arthrotomy for the Relief of Pain
Publicado: (1899)

The Relief of Pain in Childbirth
Publicado: (1934)

Surgical Relief of Pain
por: Mair, George B.
Publicado: (1944)

A Pilot, Open-Label Study to Evaluate the Efficacy of Intra-Articular Administration of a Caninized TNF Receptor Fc Fusion Protein as a Treatment for Osteoarthritis-Associated Joint Pain
por: Nakanishi, Aoi, et al.
Publicado: (2022)

Establishment of anti-mesothelioma monoclonal antibodies
por: Mizutani, Natsuko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_llu1iduoa9a6pdlntoc5birbs1